BerGenBio ASA Registered Shs News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

21.01.19	BerGenBio Announces Start of Phase I Trial Evaluating ADCT-601, a Novel Anti-AXL ADC, in Patients With Advanced Solid Tumours (PR Newswire)
21.01.19	BerGenBio Announces Start of Phase I Trial Evaluating ADCT-601, a Novel Anti-AXL ADC, in Patients With Advanced Solid Tumours (PR Newswire)
09.01.19	BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149 (PR Newswire)
09.01.19	BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149 (PR Newswire)
04.01.19	BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in High-risk MDS (PR Newswire)
04.01.19	BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in High-risk MDS (PR Newswire)
12.12.18	BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference (PR Newswire)
12.12.18	BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference (PR Newswire)
03.12.18	BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH (PR Newswire)
03.12.18	BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH (PR Newswire)
21.11.18	BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer (PR Newswire)
21.11.18	BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer (PR Newswire)
13.11.18	BerGenBio ASA: Results for the Third Quarter 2018 (PR Newswire)
13.11.18	BerGenBio ASA: Results for the Third Quarter 2018 (PR Newswire)
06.11.18	BerGenBio Reports ~80% Improvement in PFS of AXL-positive vs AXL-negative NSCLC Patients in Bemcentinib + KEYTRUDA PhII Combination Trial (PR Newswire)
06.11.18	BerGenBio Reports ~80% Improvement in PFS of AXL-positive vs AXL-negative NSCLC Patients in Bemcentinib + KEYTRUDA PhII Combination Trial (PR Newswire)
02.11.18	BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC (PR Newswire)
02.11.18	BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC (PR Newswire)
09.10.18	BerGenBio to Present Interim Phase II Clinical, Preclinical and Biomarker Data With Selective AXL Inhibitor Bemcentinib at ESMO (PR Newswire)
09.10.18	BerGenBio to Present Interim Phase II Clinical, Preclinical and Biomarker Data With Selective AXL Inhibitor Bemcentinib at ESMO (PR Newswire)
05.10.18	BerGenBio Enters Second Stage of Phase II Trial With Selective AXL Inhibitor bemcentinib in Combination With KEYTRUDA® in Patients With Advanced NSCLC (PR Newswire)
05.10.18	BerGenBio Enters Second Stage of Phase II Trial With Selective AXL Inhibitor bemcentinib in Combination With KEYTRUDA® in Patients With Advanced NSCLC (PR Newswire)
25.09.18	BerGenBio: Updated PhII Clinical Data With Selective AXL Inhibitor Bemcentinib Strengthens its Potential to Improve NSCLC Patient Outcomes (PR Newswire)
25.09.18	BerGenBio: Updated PhII Clinical Data With Selective AXL Inhibitor Bemcentinib Strengthens its Potential to Improve NSCLC Patient Outcomes (PR Newswire)
05.09.18	BerGenBio to Present Interim Phase 2 Clinical Data With Selective AXL Inhibitor Bemcentinib in Non-small Cell Lung Cancer at WCLC (PR Newswire)
05.09.18	BerGenBio to Present Interim Phase 2 Clinical Data With Selective AXL Inhibitor Bemcentinib in Non-small Cell Lung Cancer at WCLC (PR Newswire)
30.08.18	BerGenBio to Present at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 (PR Newswire)
30.08.18	BerGenBio to Present at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 (PR Newswire)
21.08.18	BerGenBio ASA: Results for the Second Quarter and First Half 2018 (PR Newswire)
21.08.18	BerGenBio ASA: Results for the Second Quarter and First Half 2018 (PR Newswire)
26.06.18	Selective AXL Inhibitor Bemcentinib Meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With KEYTRUDA® (PR Newswire)
26.06.18	Selective AXL Inhibitor Bemcentinib Meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With KEYTRUDA® (PR Newswire)
03.06.18	BerGenBio Provides Interim Update on Phase II Clinical Programme With Selective Oral AXL Inhibitor Bemcentinib (PR Newswire)
29.05.18	BerGenBio - Invitation to Conference Call: Interim Update on Ph II Clinical Programme With Selective AXL Inhibitor Bemcentinib Being Presented at ASCO (PR Newswire)
29.05.18	BerGenBio - Invitation to Conference Call: Interim Update on Ph II Clinical Programme With Selective AXL Inhibitor Bemcentinib Being Presented at ASCO (PR Newswire)
18.05.18	BerGenBio to Present Interim Clinical and Biomarker Data With Selective AXL Inhibitor Bemcentinib in AML and MDS at EHA (PR Newswire)
15.05.18	BerGenBio ASA: Results for the First Quarter 2018 (PR Newswire)
15.05.18	BerGenBio ASA: Results for the First Quarter 2018 (PR Newswire)
14.05.18	BerGenBio Participation at Upcoming Healthcare Investor and Life Sciences Industry Conferences (PR Newswire)
14.05.18	BerGenBio Participation at Upcoming Healthcare Investor and Life Sciences Industry Conferences (PR Newswire)
18.04.18	BerGenBio: Promising Data Highlighting Selective AXL Inhibitor Bemcentinib's Potential to Improve Efficacy of Checkpoint Inhibitors Presented at AACR (PR Newswire)
18.04.18	BerGenBio: Promising Data Highlighting Selective AXL Inhibitor Bemcentinib's Potential to Improve Efficacy of Checkpoint Inhibitors Presented at AACR (PR Newswire)
13.04.18	Promising Pre-clinical Data Supporting BerGenBio's Pipeline to be Published and Presented at Upcoming Leading Conferences (PR Newswire)
13.04.18	Promising Pre-clinical Data Supporting BerGenBio's Pipeline to be Published and Presented at Upcoming Leading Conferences (PR Newswire)
13.04.18	BerGenBio ASA Announces Successful NOK 187.5 Million (USD 24 Million) Private Placement of New Shares (PR Newswire)
10.04.18	BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA® (PR Newswire)
10.04.18	BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA® (PR Newswire)
22.03.18	BerGenBio to Present Overview of Phase II Clinical Trial Portfolio Combining Bemcentinib With KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe (PR Newswire)
22.03.18	BerGenBio to Present Overview of Phase II Clinical Trial Portfolio Combining Bemcentinib With KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe (PR Newswire)
15.03.18	BerGenBio: Promising Data Highlighting Bemcentinib's Potential to Improve Efficacy of Checkpoint Inhibitors to be Presented at AACR Annual Meeting (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V